Research lines

CK1 inhibitors

New roles for the old casein kinase 1, currently known as protein kinases CK1, have been recently discovered in the molecular pathology of different neurodegenerative disorders, such as Alzheimer's (AD) and Parkinson's (PD) diseases and amyotrophic lateral sclerosis (ALS). Involvement of CK1 on PD pathology and on TDP-43 phosphorylation is of utmost importance for further developments regarding a future effective treatment for PD and ALS respectively. As a consequence, specific inhibitors of this enzyme have increased their value as new therapeutic approaches for effective treatment of these devastating diseases, and in this line of research we design, synthetise and evaluate new CK1 inhibitors mainly specific of their delta and epsilon isoforms.


Mabel Loza and Maria Isabel Cadavid, PhDs. Facultad de Farmacia, Universidad de Santiago. Santiago de Compostela (Spain)

Francisca Vicente and Olga Guilloud, PhDs. Fundación de excelencia Medina. Granada (Spain)